Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.

doi:10.1016/j.jtho.2023.05.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2023

Elkrief Arielle, Odintsov Igor, Markov Vladimir, Caeser Rebecca, Sobczuk Pawel, Tischfield Sam E, Bhanot Umesh, Vanderbilt Chad M, Cheng Emily H, Drilon Alexander, Riely Gregory J, Lockwood William W, de Stanchina Elisa, Tirunagaru Vijaya G, Doebele Robert C, Quintanal-Villalonga Álvaro, Rudin Charles M, Somwar Romel, Ladanyi Marc

Abstract excerpt

INTRODUCTION: Although targeted therapies have revolutionized the therapeutic landscape of lung adenocarcinomas (LUADs), disease progression on single-agent targeted therapy against known oncogenic drivers is common, and therapeutic options after disease progression are limited. In patients with MDM2 amplification (MDM2amp) and a concurrent oncogenic driver alteration, we hypothesized that targeting of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Lung Neoplasms

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-mdm2

Share to Proto-Oncogene Proteins p21(ras)

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 37182602
DOI: 10.1016/j.jtho.2023.05.007
PMCID: PMC10524759

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.PMID 37182602Read ↗

Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted TherapySemantic proximity Read ↗

Analysis ofMDM2Amplification: Next-Generation Sequencing of Patients With Diverse MalignanciesSemantic proximity Read ↗

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Semantic proximity Read ↗

Furmonertinib Activity in NSCLC Harboring EGFR L858R and ERBB2 S310F Co-Mutations: A Case Report With Literature ReviewSemantic proximity Read ↗

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.Semantic proximity Read ↗

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.Semantic proximity Read ↗

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 SkippingSemantic proximity Read ↗

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome SequencingSemantic proximity Read ↗

Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.Semantic proximity Read ↗

ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer.Semantic proximity Read ↗

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.